TX-WP-ENGINE
10.2.2020 17:37:07 CET | Business Wire | Press release
WP Engine, the WordPress Digital Experience Platform (DXP), today announced the appointment of Lisa Box as the company’s new Senior Vice President of Corporate Development. In her new role, Lisa will be responsible for expanding WP Engine’s growth strategy, market leadership and customer value through acquisitions and strategic partnerships. Box will report to Heather Brunner, Chairwoman and Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200210005604/en/
Earlier today, Lisa Box earned a CRN 2020 Channel Chief award. She is one of the top 50 executives who were honored for their work in driving the channel agenda and evangelizing the importance of channel partnerships. This marks the third year in a row Lisa has received the accolade. Lisa and other CRN 2020 Channel Chiefs will be featured in the February issue of CRN Magazine. More information about this year’s honorees is available at www.CRN.com/ChannelChiefs .
“Lisa has been integral to our growth and success over the last four years and I’m looking forward to her building on that momentum,” said Heather Brunner. “Her extensive experience forging global partnerships with industry-leading tech companies and managing extensive M&A projects will help us continue our growth around the world as well as building strong relationships with new technology partners.”
Prior to her promotion, Box was the Vice President of Strategic Alliances and Business Development at WP Engine. Before joining WP Engine, Box held Vice President of Business Development posts at Endurance International Group and Oversee.net. She also held sales and marketing leadership roles at Internet REIT, SiteStuff and Trilogy. She was a founding member of the Forbes Business Development Council and an advisor at Wayfair Interactive. Box holds a Master of Business Administration degree and a Bachelor of Business Administration degree from Stephen F. Austin State University.
“WP Engine has a reputation for being a global leader in WordPress and I’m excited to be able to apply my energy and experience to further build upon our growth and market leadership,” said Lisa Box. “I’m looking forward to accelerating what we’re doing around M&A and strategic partnerships to bring the best possible WordPress solutions to market in service of our customers.”
Box’s appointment follows the announcement of Ramadass Prabhakar as Senior Vice President of Global Engineering at WP Engine, as well as WP Engine’s recent inclusion in nine Great Places to Work (GPTW) awards globally and counting, including GPTW for Women, GPTW in Technology, GPTW in the UK, GPTW in Ireland, and GPTW Leadership for All. WP Engine aspires to be a Workplace of Choice known for fostering a flexible, empowering, and inclusive environment for all.
About WP Engine:
The WP Engine WordPress Digital Experience Platform gives companies of all sizes the agility, performance, intelligence, and integrations they need to drive their business forward faster. WP Engine’s combination of tech innovation and an award-winning team of WordPress experts are trusted by over 100,000 companies across 150 countries to provide counsel and support, helping brands create world-class digital experiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom